Cytomegalovirus-glycoprotein vaccine (Pentamer) - Helocyte

Drug Profile

Cytomegalovirus-glycoprotein vaccine (Pentamer) - Helocyte

Alternative Names: gH/gL-PC vaccine - Helocyte; MVA-gH/gL-PC vaccine - Helocyte; Pentamer vaccine

Latest Information Update: 20 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator City of Hope National Medical Center
  • Class Cytomegalovirus vaccines; Glycoproteins; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cytomegalovirus infections

Most Recent Events

  • 16 May 2015 City of Hope has patents pending for Cytomegalovirus-specific T cell vaccine (Pentamer) globally (City of Hope website, May 2015) before May 2015
  • 16 May 2015 Immunogenicity data from a preclinical trial in Cytomegalovirus infections released by City of Hope
  • 04 May 2015 Cytomegalovirus-glycoprotein vaccine (Pentamer) licensed to DiaVax Biosciences worldwide for the prevention of Cytomegalovirus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top